Transcatheter Closure of the Patent Ductus Arteriosus: An Intention to Treat Analysis

Sheridan, B.; Ward, Cameron; Anderson, Benjamin W.; Justo, Robert

doi:10.1016/j.hlc.2012.12.007

Cited by 12 publications

(11 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Short‐and medium‐term follow up showed no significant increased Doppler velocities in the LPA and descending aorta. When compared to the data collected from much larger series of Amplatzer Ductal Occluder studies , the immediate closure rates obtained with the Occlutech ® PDA occluder was comparable. While the incidence of significant residual shunts in patients with a large PDA was somewhat higher with the Occlutech ® PDA occluder, over the course of weeks the novel Occlutech device demonstrated excellent efficacy in achieving complete closure.…”

Section: Discussionmentioning

confidence: 83%

“…Patent ductus arteriosus (PDA) is among the most common congenital heart defects. Because virtually all PDAs, regardless of size and clinical presentation require closure, transcatheter closure has gained wide acceptance with excellent long term results and the procedure has become one of the most common procedures in the treatment of congenital heart disease . Despite its remarkable safety, complications such as device embolization to the pulmonary artery and aorta have been reported, as well as mild obstruction to the LPA and descending aorta, especially in small infants with large PDAs who require a relatively large device .…”

Section: Discussionmentioning

confidence: 99%

“…Since the first successful attempt of transcatheter closure by Porstmann in 1967 a number of different devices have been developed and evaluated. Today, transcatheter closure of PDAs using nitinol‐based, self‐expanding occluder devices or coils has become the gold standard and the Amplatzer Duct Occluder (ADO) is currently among the most widely used devices . While device closure of PDAs in the current era has become a simple procedure with low risks, possible complications such as device embolization or protrusion of device into the left pulmonary artery and descending aorta, particularly in the younger age group can occur.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The new Occlutech® PDA occluder: Initial human experience

Abdelbasit

Alwi

Kandavello

et al. 2015

Cathet Cardio Intervent

View full text Add to dashboard Cite

Objectives: To evaluate the feasibility, safety, and efficacy of the Occlutech V R PDA occluder for closure of patent ductus arteriosus (PDA). Background: The Occlutech V R PDA occluder is novel, self-shaping Nitinol wire device with PET (polyethylene terephthalate) patches integrated into the shank of the device to assure a better obturation of the ductus. The Occlutech V R PDA occluder has undergone two design modifications. Methods: A prospective, non-randomized pilot study was started in November 2011. Thirty-three patients were included until April 2013. Patients weighing <6 kg or those with associated cardiac anomalies that required surgery were excluded. All patients were followed up by transthoracic echocardiography at 24 hr, 30 days, 90 days, 180 days, and 360 days after implantation. Residual shunt, left pulmonary artery (LPA) and descending aortic velocities were among the parameters assessed. All occluders were delivered via 6-8 F long sheaths and PDA closures were performed following standard techniques. Results: Thirty three patients (20 female/13 male), with a median age of 2 years (6 month to 38 years), and median weight of 9.3 kg (6-69.2 kg) were included. The narrowest median PDA diameter was 3mm (1.8-5.8 mm). All the 33 patients were closed successfully using Occlutech ductal occluder, 16 patients (48.4%) had immediate and complete closure on angiography. Within 24 hr, color Doppler revealed complete closure in 27patients (81.8%), 32patients (97%) at 30 days, and in 100% of patients at 90 days. All patients with a large PDA had immediate residual shunt which was closed at the 90-day follow-up. There was no device embolization, hemolysis, or obstruction to the LPA or descending aorta. Conclusion: The new Occlutech V R PDA is safe and effective. In patients with a large PDA complete closure tended to take longer time.

show abstract

Section: Discussionmentioning

confidence: 83%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The new Occlutech® PDA occluder: Initial human experience

Abdelbasit

Alwi

Kandavello

et al. 2015

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

“…The evolution of devices utilized has included the Raskind PDA Occluder (C.R. Bard, Ireland), Gianturco and Flipper coils (Cook Cardiology, Inc., Bloomington, IN), Nit‐Occlud coils (NOC; PFM, Cologne, Germany), and the Amplatzer Ductal Occluder (ADO) I, II, and IIAS (AGA Medical Corp., Plymouth, MN) . However, as far as pediatric patients are concerned, each of these devices may be problematic because of one or more of the following complications: risk of protrusion of the device into the aorta or pulmonary artery, relatively large sheath size for small vessels, hemodynamic instability, embolization, and difficult retrieval.…”

Section: Introductionmentioning

confidence: 99%

Catheterization Therapy vs Surgical Closure in Pediatric Patients With Patent Ductus Arteriosus: A Meta‐Analysis

Wang

Pan

Tang

et al. 2014

Clinical Cardiology

View full text Add to dashboard Cite

Background: Patent ductus arteriosus (PDA) remains a common congenital heart disease in pediatric patients, and the new trend of catheterization therapy is still associated with some potential risks and complications. Hypothesis: Compared with surgical closure, the clinical effect of catheterization therapy in pediatric PDA patients requires meta-analysis. Methods: A systematic literature search of PubMed, Cochrane Library, Embase, Science Citation Index, Web of Science, and the Chinese Biomedicine literature database was conducted. Eligible studies included controlled trials of pediatric PDA patients receiving catheterization therapy vs surgical closure. Relative risks (RRs), standard mean differences, and 95% confidence intervals (CIs) were calculated and heterogeneity was assessed with the I 2 test. Results: Seven studies with a total of 810 patients met the inclusion criteria. Catheterization therapy neither significantly increased the primary success rate (RR: 0.92, 95% CI: 0.82-1.03, P = 0.16) nor reduced the total postprocedure complications (RR: 0.74, 95% CI: 0.44-1.25, P = 0.26) and blood transfusion (RR: 1.10, 95% CI: 0.16-7.67, P = 0.93). Catheterization was associated with a statistically significant increase in residual shunts (RR: 5.19,, P = 0.01) and reduction in length of hospital stay (standard mean difference: −1.66, 95% CI: −2.65 to −0.67, P = 0.001). Conclusions: Catheterization therapy in pediatric PDA patients did not show a significant advantage in primary success rate, total complications, or blood transfusion, but it was associated with increase in residual shunts and reduction in length of hospital stay.

show abstract

“…Even though there is no clear consensus, the advantages of transcatheter closure is preferred because of the high success rates, shorter hospital stay, less blood loss, low rates of morbidity, without opening the patient's chest. This mode of treatment is particularly suitable in cases of cardiac and respiratory diseases in which the risk of surgery is increased (15).…”

Section: Discussionmentioning

confidence: 99%